Cellceutix Corp. is a clinical-stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. The company has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. The company’s lead antibiotic, Brilacidin, which has the potential to be a single-dose therapy for certain multidrug-resistant bacteria (superbugs), is preparing to be the first new class of antibiotic to enter a Phase 3 trial in more than 20 years. The company also has a clinical trial ongoing with a p53-targeting drug for advanced solid tumors at Harvard’s Dana-Farber Cancer Institute and Phase 2 trials ongoing for psoriasis and oral mucositis. Cellceutix is developing its pipeline under multiple expediting pathways of the FDA, including Orphan Drug, Fast Track and Rare Pediatric Disease designations.